Human Vaccines Market Research Report Information By Technology (Attenuated, Inactivated, Toxoid, Conjugate & Subunit, and Recombinant DNA), By Route of Administration (Oral, Injectable, and Other), By Type (Prophylactic, and Therapeutic), By Disease Indication (Pneumococcal, Influenza, Hepatitis, Rotavirus, DTP, Polio, and Others), By End User (Children, and Adults), By Composition (Mono Vaccine, and Combination Vaccine) And By Countries (Middle East and Africa) –Market Forecast Till 2032

Table of Content

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s Five Forces Model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Middle East and Africa Human Vaccines Market, by Technology

5.1 Introduction

5.1.1 Attenuated

5.1.2 Inactivated

5.1.3 Toxoid

5.1.4 Conjugate and Subunit

5.1.5 Recombinant DNA

6 Middle East and Africa Human Vaccines Market, by Disease Indication

6.1 Introduction

6.1.1 Pneumococcal

6.1.2 Influenza

6.1.3 Hepatitis

6.1.4 Rotavirus

6.1.5 DTP

6.1.6 Polio

6.1.7 Others

7 Middle East and Africa Human Vaccines Market, by Type

7.1 Introduction

7.1.1 Prophylactic

7.1.2 Therapeutic

8 Middle East and Africa Human Vaccines Market, by Composition

8.1 Introduction

8.1.1 Mono vaccine and

8.1.2 Combination vaccines

9 Middle East and Africa Human Vaccines Market, by Route of Administration

9.1 Introduction

9.1.1 Oral

9.1.2 Injectible

9.1.3 Others

10 Middle East and Africa Human Vaccines Market, by End User

10.1 Introduction

10.1.1 Children

10.1.2 Adults

11 Middle East and Africa Human Vaccines Market, by Country

11.1 Introduction

11.1.2 UAE

11. 1.3 Egypt

11. 1.4 Saudi Arabia

11. 1.5 Kuwait

11. 1.6 Qatar

11. 1.7 Oman

12 Company Landscape

12.1 Introduction

12.1.1 Mergers Acquisitions

12.1.2 Collaborations

12.1.3 Release/New Product Launches

12.1.4 Other (Expansion, Updates, Partnership)

13 Company Profile

13.1 GlaxoSmithKline Plc.

13.1.1 Company Overview

13.1.2 Product/Business Segment Overview

13.1.3 Financials

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Merck & Co. Inc.

13.2.1 Overview

13.2.2 Product/Business Segment Overview

13.2.3 Financials

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Pfizer, Inc.

13.3.1 Overview

13.3.2 Product/Business Segment Overview

13.3.3 Financials

13.3.4 Key Developments

13.3.5 SWOT Analysis

13.4 Sanofi Pasteur, Inc.

13.4.1 Overview

13.4.2 Product/Business Segment Overview

13.4.3 Financials

13.4.4 Key Developments

13.4.5 SWOT Analysis

13.5 AstraZeneca Plc.

13.5.1 Overview

13.5.2 Product/Business Segment Overview

13.5.3 Financials

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 Bharat Biotech

13.6.1 Overview

13.6.2 Product/Business Segment Overview

13.6.3 Financials

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Shenzhen Kangtai Biological Products

13.7.1 Overview

13.7.2 Product/Business Segment Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Valeant Pharmaceuticals

13.8.1 Overview

13.8.2 Product/Business Segment Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Emergent Biosolutions Inc.

13.9.1 Overview

13.9.2 Product/Business Segment Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 Astellas Pharma Inc.

13.10.1 Overview

13.10.2 Product/Business Segment Overview

13.10.3 Financials

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.11 Panacea Biotec

13.11.1 Overview

13.11.2 Product/Business Segment Overview

13.11.3 Financials

13.11.4 Key Developments

13.11.5 SWOT Analysis

14 Others

15 Appendix

List of Tables

TABLE 1 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, 2023-2030 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION, 2023-2030 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER, 2023-2030 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION, 2023-2030 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY

FIGURE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION

FIGURE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE

FIGURE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION

FIGURE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER

FIGURE 9 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION

FIGURE 10 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET: COMPANY SHARE ANALYSIS, 2020 (%)